News

4936 articles

Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

January 20, 2026

Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug (IND) application. The agreement spans across all indications currently pursued by Bayer, initially focusing on cardiovascular and kidney diseases, two therapeutic areas with significant unmet medical need.

© Copyright 2026 Tri-County Publishing, Inc. | Privacy | Terms
Powered by Novel.ad